查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476425

骨關節炎治療的全球市場預測（-2030）：按治療方法、解剖學、給藥途徑、分銷管道和區域的分析

Osteoarthritis Therapeutics Market Forecasts to 2030 - Global Analysis By Treatment, Anatomy, Route of Administration, Distribution Channel and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

2023年，全球骨關節炎治療市場規模為96億美元，預計在預測期內年複合成長率為9.7%，到2030年將達到184億美元。骨關節炎治療的目的在於控制疼痛、改善關節功能並減緩疾病進展。

非藥物介入包括運動、體重管理和物理治療。藥物選擇包括止痛藥，如對乙醯胺酚和非類固醇抗發炎藥物來緩解疼痛，關節內注射皮質類固醇和透明質酸可以緩解症狀。也使用葡萄糖胺和硫酸軟骨素等緩解疾病的藥物，但其有效性存在爭議。在嚴重的情況下，也可以考慮手術干預，例如關節重建。

根據《Lancet》誌2023年 9月發表的一項研究，2020年全球有 5.95 億人患有骨關節炎，亞太地區的盛行率為每 10 萬人中 8,632.7 人。如此高的數字表明該地區對治療藥物的需求不斷增加。

對疼痛管理的需求不斷成長

隨著越來越多的人尋求骨關節炎疼痛的解決方案，對骨關節炎治療的整體需求也在增加。這意味著隨著越來越多的患者需要這些治療，市場將會擴大，提供這些治療的製藥公司和醫療保健提供者的收益增加，以及骨關節炎特異性止痛藥物的開發，這將導致行銷的開展。這包括非類固醇抗發炎藥和止痛藥等口服藥物、乳霜和凝膠等外用藥物以及皮質類固醇和透明質酸等注射藥物，以增強疼痛管理並進一步促進市場成長。

藥物副作用

骨關節炎治療會帶來令人不快或嚴重的副作用，這可能會使患者不太可能按處方服用藥物。結果，疼痛和發炎可能變得不受控制，可能使病情惡化並增加醫療費用。也可能會出現需要進一步治療的併發症，例如非類固醇抗發炎藥物引起的胃潰瘍。這給醫療保健系統和個人預算帶來了壓力。藥物使用的不一致也會降低治療效果並阻礙整體市場表現。

骨關節炎盛行率上升

隨著越來越多的人被診斷出患有骨關節炎，對治療的需求自然會增加，有助於在早期階段控制骨關節炎，並在後期需要強化藥物治療或關節關節重建，以減緩或預防疾病的治療方法引起人們的注意。這將為提供骨關節炎治療的製藥公司和醫療保健提供者帶來不斷成長的市場。

疾病改善有限

由於不能改變病程，重複患者較多。隨著骨關節炎的惡化，患者可能需要使用相同或逐漸更強的藥物進行持續的治療方法，也可能導致患者對現有治療方法的不滿。患者可能會覺得他們的症狀沒有有效解決，因為儘管使用藥物，疼痛和關節惡化仍然持續。這給患者和醫療保健系統造成了重複成本的循環，阻礙了市場成長。

COVID-19 的影響

遠端醫療和遠端監控已成為人們關注的焦點，並影響了處方模式。對緩解症狀的需求仍在繼續，但經濟不確定性可能影響了負擔能力和獲得治療的機會。儘管研發面臨挑戰，但也存在創新機會，特別是在遠端病患管理和虛擬臨床試驗方面。總體而言，COVID-19 凸顯了適應性、以患者為中心的方法和適應力在骨關節炎治療市場動態中的重要性。

關節關節內粘稠補充療法預計在預測期內將是最大的

由於關節內粘稠補充療法提供了一種替代治療選擇，預計該細分市場將出現良好的成長，特別是對於其他傳統療法（如非類固醇消炎劑和皮質類固醇注射）沒有反應的 OA 患者。這些藥物使骨關節炎患者的治療選擇多樣化。這使得醫生能夠根據患者的個別需求和偏好制定治療計劃，採用更個人化的疾病管理方法。

預計膝骨關節炎領域在預測期內年複合成長率最高

膝骨關節炎是膝骨關節炎最常見的形式之一，導致對緩解疼痛、減少發炎和改善關節功能的治療藥物的大量需求，預計該領域將以最高的年複合成長率成長。這種高需求推動製藥公司的研發工作，以創新和改進現有治療方法，並開發專門針對膝骨關節炎的新治療方法。

佔有率最大的地區

由於醫療保健支出增加、人口成長、醫療進步、監管支持和意識增強，預計亞太地區將在預測期內佔據最大的市場佔有率。在中國、日本和印度等國家人口老化和治療創新的推動下，亞太地區預計將顯著成長。製藥公司投資產品開發的合作研究，有利的監管環境推動對症狀和疾病緩解療法的需求。

年複合成長率最高的地區：

由於肥胖率高和政府支持政策等多種因素，預計北美在預測期內將呈現最高的年複合成長率。Novartis AG、Pfizer、Zimmer Biomet、GlaxoSmithKline plc等主要市場參與者進一步鞏固其地位。製藥巨頭之間的治療研究試驗、合併、收購和聯盟等策略性舉措積極塑造競爭格​​局。例如，2024年2月，諾華宣布進一步繼續一項生物干預研究，檢視膝骨關節炎患者關節內注射卡那奴單抗和LNA043的安全性、耐受性和有效性。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場公司的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 新興市場
  • COVID-19 的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球骨關節炎治療市場：依治療方法

  • 關節內粘稠補充療法劑
  • 皮質類固醇
  • 玻尿酸注射
  • 非類固醇消炎劑（NSAID）
    • Naproxen
    • 雙氯芬酸鈉
    • 阿斯匹靈
    • Ibuprofen
  • 止痛藥
    • 乙醯胺酚
    • Duloxetine
  • 其他治療方法

第6章 全球骨關節炎治療市場：解剖結構

  • 髖骨關節炎
  • 手骨關節炎
  • 小關節骨關節炎
  • 膝骨關節炎
  • 踝骨關節炎
  • 其他解剖結構

第7章 全球骨關節炎治療市場：依給藥途徑

  • 腸外給藥
  • 局部給藥
  • 口服給藥
  • 其他給藥途徑

第8章 全球骨關節炎治療市場：按分銷管道

  • 醫院藥房
  • 零售藥房
  • 藥局
  • 電子商務

第9章 全球骨關節炎治療市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東、非洲

第10章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第11章 公司概況

  • GlaxoSmithKline plc
  • Sanofi SA
  • Bayer AG
  • Pfizer Inc
  • Novartis AG
  • Zimmer Biomet
  • Assertio Therapeutics, INC.
  • Anika Therapeutics
  • Bioventus
  • Ferring Pharmaceuticals Inc.
  • Abbvie Inc.
  • Amgen Inc.
  • Boehringer Ingelheim International GmbH.
  • Samsung Bioepis.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals Industries Ltd.
  • AstraZeneca PLC
  • Stryker Corporation
  • Merck & Co Inc.
Product Code: SMRC25971

According to Stratistics MRC, the Global Osteoarthritis Therapeutics Market is accounted for $9.6 billion in 2023 and is expected to reach $18.4 billion by 2030 growing at a CAGR of 9.7% during the forecast period. Osteoarthritis therapeutics aim to manage pain, improve joint function, and slow disease progression. Non-pharmacological interventions include exercise, weight management, and physical therapy. Pharmacological options encompass analgesics like acetaminophen and NSAIDs for pain relief, while intra-articular injections of corticosteroids or hyaluronic acid may alleviate symptoms. Disease-modifying drugs such as glucosamine and chondroitin sulfate are also utilized, albeit their efficacy is debated. Surgical interventions like joint replacement surgery are considered in severe cases.

According to a study published by The Lancet in September 2023, globally, 595 million people had osteoarthritis in 2020, with the Asia Pacific region accounting for a prevalence of 8632.7 per 100,000. Such high figures indicate an increasing demand for therapeutics in the region.

Market Dynamics:

Driver:

Growing demand for pain management

As more people seek solutions for osteoarthritis pain, the overall demand for osteoarthritis therapeutics rises. This translates to a larger market with more patients requiring treatment, leading to increased revenue for pharmaceutical companies and healthcare providers offering these therapies and development and marketing of pain-relieving medications specifically designed for osteoarthritis. This includes oral medications like NSAIDs and analgesics, topical applications like creams and gels, and injectable options like corticosteroids and hyaluronic acid enhancing the pain management and further boosting the market growth.

Restraint:

Adverse side effects of medications

Osteoarthritis medications come with unpleasant or even serious side effects, patients might be less likely to take them as prescribed. This can lead to uncontrolled pain, inflammation, and potentially a worsening of the condition and can lead to additional healthcare costs. Patients might experience complications requiring further treatment, such as stomach ulcers from NSAIDs. This puts a strain on healthcare systems and individual budgets. Thus inconsistency in medication use also reduces the effectiveness of the treatment, hindering the overall market performance.

Opportunity:

Rising prevalence of osteoarthritis

As more and more people are diagnosed with osteoarthritis, the demand for treatments naturally increases and focuses on treatments that can help manage osteoarthritis in its early stages, potentially delaying or preventing the need for stronger medications or joint replacements later. This translates to a larger market for pharmaceutical companies and healthcare providers offering osteoarthritis therapeutics.

Threat:

Limited disease modification

The inability to modify the disease course often leads to repeat customers. Patients may require ongoing treatment regimens with the same or progressively stronger medications as their osteoarthritis worsens and can also lead to patient dissatisfaction with available treatments. Patients might feel their condition is not being effectively addressed, as they experience ongoing pain and joint deterioration despite medication use. This creates a cycle of recurring costs for patients and healthcare systems hampering the market growth.

Covid-19 Impact

Telemedicine and remote monitoring gained prominence, influencing prescribing patterns. While demand for symptomatic relief persisted, economic uncertainties may have affected affordability and access to treatments. Research and development efforts faced challenges, but also opportunities for innovation, particularly in remote patient management and virtual clinical trials. Overall, COVID-19 underscored the importance of adaptability, patient-centric approaches, and resilience in navigating market dynamics for osteoarthritis therapeutics.

The viscosupplementation agents segment is expected to be the largest during the forecast period

The viscosupplementation agents segment is estimated to have a lucrative growth, as these agents provide an alternative treatment option for OA patients, especially those who do not respond well to other conventional therapies like NSAIDs or corticosteroid injections. These agents have diversified the treatment options available for osteoarthritis patients. This has led to a more personalized approach to managing the condition, as physicians can now tailor treatment plans based on individual patient needs and preferences.

The knee osteoarthritis segment is expected to have the highest CAGR during the forecast period

The knee osteoarthritis segment is anticipated to witness the highest CAGR growth during the forecast period, because knee osteoarthritis is one of the most common forms of OA, leading to a substantial demand for therapeutics targeting pain relief, inflammation reduction, and improvement in joint function. This high demand drives research and development efforts by pharmaceutical companies to innovate and improve existing treatments or develop new ones specifically tailored for knee osteoarthritis.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increased healthcare spending, population growth, medical advancements, regulatory support, and improved awareness. It's projected to experience significant growth, driven by aging populations and treatment innovation in countries such as China, Japan, and India. Pharmaceutical firms are investing in research collaborations for product development, and a favorable regulatory scenario, driving demand for both symptomatic relief and disease-modifying treatments.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, due to various factors, including the region's high prevalence of obesity and supportive government policies. Key market players such as Novartis AG, Pfizer, Zimmer Biomet, and GlaxoSmithKline plc further solidify its position. Strategic initiatives such as therapeutics study trials, mergers, acquisitions, and partnerships among pharmaceutical giants are actively shaping the competitive landscape. For instance, in February 2024, Novartis announced further continuation of its study for biological interventions U.S., which are safety, tolerability and efficacy of intra-articular Canakinumab and LNA043 for patients with knee osteoarthritis

Key players in the market

Some of the key players in the Osteoarthritis Therapeutics Market include GlaxoSmithKline plc, Sanofi SA, Bayer AG, Pfizer Inc, Novartis AG, Zimmer Biomet, Assertio Therapeutics, INC., Anika Therapeutics, Bioventus, Ferring Pharmaceuticals Inc., Abbvie Inc., Amgen Inc., Boehringer Ingelheim International GmbH., Samsung Bioepis., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca PLC, Stryker Corporation and Merck & Co Inc.

Key Developments:

In April 2024, Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2. This does not impact patient use or commercial supply of Kisqali(R) in its approved indication of metastatic breast cancer (mBC).

In March 2024, ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges.

In February 2024, GSK plc announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

Treatments Covered:

  • Viscosupplementation Agents
  • Corticosteroids
  • Hyaluronic Acid Injection
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Analgesics
  • Other Treatments

Anatomies Covered:

  • Hip Osteoarthritis
  • Hand Osteoarthritis
  • Small-Joint Osteoarthritis
  • Knee Osteoarthritis
  • Ankle Osteoarthritis
  • Other Anatomies

Route of Administrations Covered:

  • Parenteral Route
  • Topical Route
  • Oral Route
  • Other Route of Administrations

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • E-Commerce

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Osteoarthritis Therapeutics Market, By Treatment

  • 5.1 Introduction
  • 5.2 Viscosupplementation Agents
  • 5.3 Corticosteroids
  • 5.4 Hyaluronic Acid Injection
  • 5.5 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
    • 5.5.1 Naproxen
    • 5.5.2 Diclofenac
    • 5.5.3 Aspirin
    • 5.5.4 Ibuprofen
  • 5.6 Analgesics
    • 5.6.1 Acetaminophen
    • 5.6.2 Duloxetine
  • 5.7 Other Treatments

6 Global Osteoarthritis Therapeutics Market, By Anatomy

  • 6.1 Introduction
  • 6.2 Hip Osteoarthritis
  • 6.3 Hand Osteoarthritis
  • 6.4 Small-Joint Osteoarthritis
  • 6.5 Knee Osteoarthritis
  • 6.6 Ankle Osteoarthritis
  • 6.7 Other Anatomies

7 Global Osteoarthritis Therapeutics Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Parenteral Route
  • 7.3 Topical Route
  • 7.4 Oral Route
  • 7.5 Other Route of Administrations

8 Global Osteoarthritis Therapeutics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Drug Stores
  • 8.5 E-Commerce

9 Global Osteoarthritis Therapeutics Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 GlaxoSmithKline plc
  • 11.2 Sanofi SA
  • 11.3 Bayer AG
  • 11.4 Pfizer Inc
  • 11.5 Novartis AG
  • 11.6 Zimmer Biomet
  • 11.7 Assertio Therapeutics, INC.
  • 11.8 Anika Therapeutics
  • 11.9 Bioventus
  • 11.10 Ferring Pharmaceuticals Inc.
  • 11.11 Abbvie Inc.
  • 11.12 Amgen Inc.
  • 11.13 Boehringer Ingelheim International GmbH.
  • 11.14 Samsung Bioepis.
  • 11.15 Sun Pharmaceutical Industries Ltd.
  • 11.16 Teva Pharmaceuticals Industries Ltd.
  • 11.17 AstraZeneca PLC
  • 11.18 Stryker Corporation
  • 11.19 Merck & Co Inc.

List of Tables

  • Table 1 Global Osteoarthritis Therapeutics Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Osteoarthritis Therapeutics Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 3 Global Osteoarthritis Therapeutics Market Outlook, By Viscosupplementation Agents (2021-2030) ($MN)
  • Table 4 Global Osteoarthritis Therapeutics Market Outlook, By Corticosteroids (2021-2030) ($MN)
  • Table 5 Global Osteoarthritis Therapeutics Market Outlook, By Hyaluronic Acid Injection (2021-2030) ($MN)
  • Table 6 Global Osteoarthritis Therapeutics Market Outlook, By Non-steroidal Anti-inflammatory Drugs (NSAIDs) (2021-2030) ($MN)
  • Table 7 Global Osteoarthritis Therapeutics Market Outlook, By Naproxen (2021-2030) ($MN)
  • Table 8 Global Osteoarthritis Therapeutics Market Outlook, By Diclofenac (2021-2030) ($MN)
  • Table 9 Global Osteoarthritis Therapeutics Market Outlook, By Aspirin (2021-2030) ($MN)
  • Table 10 Global Osteoarthritis Therapeutics Market Outlook, By Ibuprofen (2021-2030) ($MN)
  • Table 11 Global Osteoarthritis Therapeutics Market Outlook, By Analgesics (2021-2030) ($MN)
  • Table 12 Global Osteoarthritis Therapeutics Market Outlook, By Acetaminophen (2021-2030) ($MN)
  • Table 13 Global Osteoarthritis Therapeutics Market Outlook, By Duloxetine (2021-2030) ($MN)
  • Table 14 Global Osteoarthritis Therapeutics Market Outlook, By Other Treatments (2021-2030) ($MN)
  • Table 15 Global Osteoarthritis Therapeutics Market Outlook, By Anatomy (2021-2030) ($MN)
  • Table 16 Global Osteoarthritis Therapeutics Market Outlook, By Hip Osteoarthritis (2021-2030) ($MN)
  • Table 17 Global Osteoarthritis Therapeutics Market Outlook, By Hand Osteoarthritis (2021-2030) ($MN)
  • Table 18 Global Osteoarthritis Therapeutics Market Outlook, By Small-Joint Osteoarthritis (2021-2030) ($MN)
  • Table 19 Global Osteoarthritis Therapeutics Market Outlook, By Knee Osteoarthritis (2021-2030) ($MN)
  • Table 20 Global Osteoarthritis Therapeutics Market Outlook, By Ankle Osteoarthritis (2021-2030) ($MN)
  • Table 21 Global Osteoarthritis Therapeutics Market Outlook, By Other Anatomies (2021-2030) ($MN)
  • Table 22 Global Osteoarthritis Therapeutics Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 23 Global Osteoarthritis Therapeutics Market Outlook, By Parenteral Route (2021-2030) ($MN)
  • Table 24 Global Osteoarthritis Therapeutics Market Outlook, By Topical Route (2021-2030) ($MN)
  • Table 25 Global Osteoarthritis Therapeutics Market Outlook, By Oral Route (2021-2030) ($MN)
  • Table 26 Global Osteoarthritis Therapeutics Market Outlook, By Other Route of Administrations (2021-2030) ($MN)
  • Table 27 Global Osteoarthritis Therapeutics Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 28 Global Osteoarthritis Therapeutics Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
  • Table 29 Global Osteoarthritis Therapeutics Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 30 Global Osteoarthritis Therapeutics Market Outlook, By Drug Stores (2021-2030) ($MN)
  • Table 31 Global Osteoarthritis Therapeutics Market Outlook, By E-Commerce (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.